Robert J. Kelley - 01 Jun 2022 Form 4 Insider Report for Talis Biomedical Corp

Role
Chief Executive Officer, Director
Signature
/s/ J. Roger Moody, Jr., Attorney-in-Fact for Robert J. Kelley
Issuer symbol
TLIS on OTC
Transactions as of
01 Jun 2022
Net transactions value
$0
Form type
4
Filing time
02 Jun 2022, 17:23:51 UTC
Previous filing
09 Dec 2021
Next filing
11 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TLIS Stock Option (right to buy) Award $0 +723,560 $0.000000 723,560 01 Jun 2022 Common Stock 723,560 $1.03 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3 of awards vest as follows: 25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date of June 1, 2022 (VCD) and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.
F2 1/3 of the shares shall vest on the seventh anniversary of the VCD, subject to optionholder's continuous service as of such date, provided that such vesting shall be subject to acceleration based upon certain pre-determined commercial and regulatory milestones.
F3 1/3 of the shares shall vest on the seventh anniversary of the VCD, subject to optionholder's continuous service as of such date, provided that such vesting shall be subject to partial or full acceleration based on pre-determined closing prices of the Company's common stock sustained for a certain number of consecutive trading days.